ImmunoPrecise Antibodies Other Current Liabilities

ImmunoPrecise Antibodies (IPA) currently reports a other current liabilities of $330K as of January 2026. That compares with $300K in the prior-year period — up 10.9% year over year. Use the charts on this page to explore ImmunoPrecise Antibodies's other current liabilities history and peer comparisons.

ImmunoPrecise Antibodies's other current liabilities increased from $300K to $330K — a 10.9% year-over-year increase (period ending January 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

ImmunoPrecise Antibodies reported $330K in other current liabilities as of January 2026. That compares with $300K in the prior-year period — up 10.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current other current liabilities of $330K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for ImmunoPrecise Antibodies, and consider following IPA for alerts when major investors trade the stock.

ImmunoPrecise Antibodies is classified in the Healthcare sector. On other current liabilities, it currently shows $330K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing IPA with unrelated industries.